Dementia Australia has welcomed the publication of the results of a trial showing that a new drug, donanemab, has been able to slow the progression
Eli Lilly and Company’s new drug, donanemab, has shown promising results in slowing cognitive decline by 35% in people with early symptoms of Alzheimer’s disease.
Healthcare Channel – Sharing knowledge and resources for Australia’s health and aged care sector
We always welcome thought leaders ready to mentor the next generation. Be a Healthcare Channel learning partner today!
Healthcare Channel acknowledges the traditional custodians of the lands where we live, learn and work. We pay our respects to Elders past, present and emerging.
Healthcare Channel acknowledges the traditional custodians of the lands where we live, learn and work. We pay our respects to Elders past, present and emerging.
